Thrombolytic stroke therapy, such as tissue plasminogen activator (tPA), facilitates the cleavage of plasminogen to plasmin, which in turn degrades the fibrin meshwork, leading to clot dissolution [1]. The gene discussed is PLG; the disease is stroke disorder.